Online inquiry

IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15351MR)

This product GTTS-WQ15351MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ENG gene. The antibody can be applied in Sarcoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_000118.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2022
UniProt ID P17813
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ENG, TRC-105(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15351MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5023MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA c4G7-N
GTTS-WQ12986MR IVTScrip™ mRNA-Anti-TNF, PEG sTNF-RI(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PEG sTNF-RI
GTTS-WQ15426MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA TSR-033
GTTS-WQ4026MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BI 655066
GTTS-WQ699MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA A-1230717
GTTS-WQ3045MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ12444MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NKTR-214
GTTS-WQ1187MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABP 980
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW